Search 

Accucaps Industries specializes in soft gel formulations and operates a full R&D organization, developing and supporting projects from early research to life cycle management. We are continually engaged with potential partners in exploring how our broad therapeutic portfolio, formulation, clinical development and manufacturing expertise combined with strong customer relationships, can yield mutually beneficial business relationships.

Our Product Innovation team has developed technologies which may enhance bioavailability through advanced technologies incorporated into the design of various formulation solutions within soft gel capsules.  Some of these technologies may assist your organization in maintaining their leading position with their top products through additional lifecycle options.

AcelRx is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. Our lead product, ARX-01, is currently being evaluated in Phase 3 studies for the treatment of moderate to severe acute pain in the hospital setting. ARX-01 is designed to enable patient control, remove impediments to ambulation, and improve patient satisfaction. By utilizing sublingual delivery of sufentanil NanoTabs(R) thorugh our proprietary handheld system, ARX-01 avoids the invasive IV route of delivery and the inherent potential for programming and delivery errors associated with the complexity of infusion pumps. By delivering sufentanil through the oral transmucosal route, ARX-01 offers the potential to improve upon the typical side effect profile of morphine. 

We have three additional product candidates in clinical development: ARX-02 for the treatment of cancer breakthrough pain; ARX-03 for providing mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician’s office; and ARX-04, a non-invasive, fast-onset sublingual product for the treatment of moderate-to-severe acute pain.

Avanir Pharmaceuticals, Inc. is a biotechnology company focused on acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders.  Our lead product, NUEDEXTA, is a dual sigma-1/NMDA receptor modulator and is the first and only FDA-approved treatment for pseudobulbar affect (PBA).  PBA is a condition affecting many patients with Alzheimer's / dementia, stroke, MS, Parkinson's, and other forms of neurological disease or injury and is characterized by uncontrolled episodes of crying or laughing.  

Avanir is commercializing NUEDEXTA in the United States through its specialty sales force calling primarily on neurology and psychiatry clinics as well as nursing homes.  Recent commercial milestones include over 10,000 Rx's during the month of August 2012 (up 9% relative to the prior month), which equates to a gross NUEDEXTA sales run-rate of over $65 million per year.

Avanir has a pending MAA for NUEDEXTA with the European regulatory authorities and is also conducting clinical trials in additional indications such as agitation in dementia, neuropathic pain in multiple sclerosis, and other areas where dual sigma-1/NMDA receptor targeted therapies can address unmet needs.    

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting with a current focus on already marketed or near to market hospital products.

Cadence has a highly experienced commercial group of 140+ hospital sales specialists, 14 MSLs and marketing team which are focused entirely on promotion to the hospital in the United States.  Our sales force is currently promoting OFIRMEV™ (acetaminophen injection), which is indicated for the treatment of acute pain and fever and we are now looking to expand our product offering.

Cornerstone Therapeutics Inc. is a specialty pharmaceutical company focused on commercializing products for the hospital, niche respiratory and related specialty markets. Key elements of the Company’s strategy are to focus its commercial and development efforts in the hospital and related specialty product sector within the U.S. pharmaceutical marketplace; continue to seek out opportunities to acquire companies and marketed and/or registration-stage products that fit within the Company’s focus areas; and generate revenues by marketing approved generic products through the Company’s wholly owned subsidiary, Aristos Pharmaceuticals, Inc. 

Depomed, Inc. (Nasdaq:  DEPO) is a US based specialty pharmaceutical company with a focus in pain, CNS, and Women's Health.  The company has advanced three products to market and has developed a pipeline with late-stage product opportunities intended to address common medical conditions affecting large patient populations

Depomed is currently seeking US co-promotion, and Global license partners for it's marketed product Gralise (once-daily gabapentin for Post Herpetic Neuralgia), and Serada a non-hormonal treatment for Vasomotor Symptoms (menopausal hot flashes) which is currently under in registration.